INDIANAPOLIS, May 8, 2020 /PRNewswire/ — New 36-week data showed higher investigational doses of Trulicity (3 mg and 4.5 mg) were well-tolerated and led to A1C reductions up to 1.9 percent and weight reductions up to 10.4 pounds in people with type 2 diabetes. Juan Pablo Frias, M.D., Medical Director and Principal Investigator, National Research
